Comment from American Association of Pharmaceutical Scientists (AAPS)

Summary: The American Association of Pharmaceutical Scientists (AAPS) supports the proposed guidance but requests specific updates to include continuous manufacturing technologies, nanomills, acoustic mixing, and amorphous solid dispersions. They also advocate for expanding excipient categories to include lipid-based drug delivery systems and clarifying risk assessments for manufacturing transfers between different organizations (e.g., CDMOs).